3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
7
Leukemia, Myeloid, Acute
5
Neuroblastoma
2
Neoplasm Metastasis
2
Thyroid Neoplasms
1
Sarcoma, Myeloid
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Hepatoblastoma
1
Gastrointestinal Stromal Tumors
1
Fibrolamellar hepatocellular carcinoma
1
Interventions
X-Rays
7
Phantoms, Imaging
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vincristine
2
Temozolomide
2
LY3023414
2
Fluorouracil
2
Doxorubicin
2
Cisplatin
2
Carboplatin
2
talazoparib
1
sodium thiosulfate
1
pembrolizumab
1
olaparib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatoblastoma
×
Sorafenib
×
90 days
×
Clear all
NCT03017326
2026-05-13
PHITT
University of Birmingham
Phase 3
Active not recruiting
450 enrolled